Record-breaking billion-dollar sales of the RCB and RR franchises have triggered a valuation re-rating across the IPL ...
RCD Espanyol’s rise to La Liga mid-table stability under Velocity Sports Partners blends data-driven recruitment, academy ...
Highlights for FY26 Q4 Revenues of $2,457.3 million, an increase of 16.0% compared to last year, driven by a favourable ORV ...
Q4 2025. Management View. CEO Joshua Riggs announced the submission of GraftAssureDx to the FDA, emphasizing, “ ...
Hamill stated, "While we are not providing detailed formal guidance for fiscal year 2026 at this time, I do want to share our directional expectations for the combined business." Management expects ...
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its business update and ...
Highlights for FY26 Q4 Revenues of $2,457.3 million, an increase of 16.0% compared to last year, driven by a favourable ORV product mix, as well as higher ORV and ...
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, includi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results